From GlobeNewswire: 2025-05-30 21:00:00

Teva Pharmaceuticals announced real-world data showing improved outcomes for UZEDY in treating schizophrenia compared to daily oral options. The Phase 3 SOLARIS study of TEV-‘749 showed no PDSS events after 3,400 injections. UZEDY had lower relapse rates, better adherence, and lower healthcare costs. TEV-‘749 met efficacy endpoints with no new safety concerns. Teva is committed to providing long-acting treatments for schizophrenia. The data were presented at the 2025 Psych Congress Elevate Annual Meeting. UZEDY and TEV-‘749 utilize SteadyTeq™ technology for controlled release of risperidone and olanzapine. UZEDY is approved for schizophrenia treatment in adults.



Read more at GlobeNewswire: Teva Presents Latest Schizophrenia Portfolio Data Including